Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.14-1.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Tonix is expanding TONMYA coverage under Medicaid to 75 million beneficiaries. The company is advancing clinical trials for TNX-4800 and TNX-1500. These steps could lead to future revenue growth and product approvals.
Tonix is currently loss-making with negative earnings and cash flow. Clinical programs face delays and mixed progress. The recent selloff and multiple negative events show risks remain high.
The stock price is about 44% below our valuation level, reflecting skepticism on near-term earnings and growth. Our view differs by seeing potential if coverage and trials progress, but risks remain.
Breaks if: No positive clinical updates or trial progress in 2026
Breaks if: Adaptive Phase 2 study initiation delayed beyond H1 2027
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, given its focus on advancing clinical developments and expanding patient access. The current thesis is cautious, reflecting recent volatility in management and financial performance.
The market appears to price in a low level of fragility, suggesting that investors are not overly concerned about immediate risks. However, TNXP is seen as cheap compared to its peers, indicating that expectations may be lower than for other companies in the healthcare sector.
Fundamentals may show mixed results in the near term. While there is progress in expanding access to TONMYA and advancing clinical trials, recent financial performance has been weak and management remains volatile.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX. If these companies continue to perform well, it could benefit TNXP. Conversely, any negative shifts in their performance could adversely affect TNXP's outlook.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats to the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: TONMYA coverage falls below 70 million Medicaid beneficiaries next quarter
Over the next 1 to 3 years, TNXP's performance will depend on sector trends and management execution. Not investment advice.